Biotechnological company aiming to treat haematological malignancies and solid tumors with γδ T cells treatment. The headquarters was located in the UK. It is driven to improve outcomes and survival in cancer patients with the therapy based on unique properties of Vδ1+ T cells. GammaDelta is the only company with the capability to generate both blood-and tissue-derived allogeneic immunotherapies with Vδ1+ T cells.